Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma

Impact of dose on treatment outcomes

Dirk Rades, Lena Sehmisch, Stefan Huttenlocher, Oliver Blank, Dagmar Hornung, Patrick TerheydeN, Jan Gliemroth, Steven E. Schild

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.

Original languageEnglish (US)
Pages (from-to)5079-5082
Number of pages4
JournalAnticancer Research
Volume34
Issue number9
StatePublished - Sep 1 2014

Fingerprint

Radiosurgery
Melanoma
Neoplasm Metastasis
Brain
L-Lactate Dehydrogenase
Survival
Multivariate Analysis

Keywords

  • Brain metastases
  • Melanoma
  • Radiosurgery

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rades, D., Sehmisch, L., Huttenlocher, S., Blank, O., Hornung, D., TerheydeN, P., ... Schild, S. E. (2014). Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: Impact of dose on treatment outcomes. Anticancer Research, 34(9), 5079-5082.

Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma : Impact of dose on treatment outcomes. / Rades, Dirk; Sehmisch, Lena; Huttenlocher, Stefan; Blank, Oliver; Hornung, Dagmar; TerheydeN, Patrick; Gliemroth, Jan; Schild, Steven E.

In: Anticancer Research, Vol. 34, No. 9, 01.09.2014, p. 5079-5082.

Research output: Contribution to journalArticle

Rades, D, Sehmisch, L, Huttenlocher, S, Blank, O, Hornung, D, TerheydeN, P, Gliemroth, J & Schild, SE 2014, 'Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: Impact of dose on treatment outcomes', Anticancer Research, vol. 34, no. 9, pp. 5079-5082.
Rades D, Sehmisch L, Huttenlocher S, Blank O, Hornung D, TerheydeN P et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: Impact of dose on treatment outcomes. Anticancer Research. 2014 Sep 1;34(9):5079-5082.
Rades, Dirk ; Sehmisch, Lena ; Huttenlocher, Stefan ; Blank, Oliver ; Hornung, Dagmar ; TerheydeN, Patrick ; Gliemroth, Jan ; Schild, Steven E. / Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma : Impact of dose on treatment outcomes. In: Anticancer Research. 2014 ; Vol. 34, No. 9. pp. 5079-5082.
@article{3b874ba8b0cd4f138be776e80b4eaf72,
title = "Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: Impact of dose on treatment outcomes",
abstract = "Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72{\%} after 20 Gy and 100{\%} after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.",
keywords = "Brain metastases, Melanoma, Radiosurgery",
author = "Dirk Rades and Lena Sehmisch and Stefan Huttenlocher and Oliver Blank and Dagmar Hornung and Patrick TerheydeN and Jan Gliemroth and Schild, {Steven E.}",
year = "2014",
month = "9",
day = "1",
language = "English (US)",
volume = "34",
pages = "5079--5082",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma

T2 - Impact of dose on treatment outcomes

AU - Rades, Dirk

AU - Sehmisch, Lena

AU - Huttenlocher, Stefan

AU - Blank, Oliver

AU - Hornung, Dagmar

AU - TerheydeN, Patrick

AU - Gliemroth, Jan

AU - Schild, Steven E.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.

AB - Background/Aim: To compare different doses of stereotactic radiosurgery (SRS) for 1-3 newly-diagnosed cerebral metastases from melanoma. Patients and Methods: Fifty-four patients were assigned to dose groups of 20 Gy (N=36) and 21-22.5 Gy (N=18). Variables additionally analyzed were age, gender, Karnofsky Performance Score (KPS), lactate dehydrogenase (LDH) before SRS, number of cerebral lesions, extracranial lesions, time from melanoma diagnosis to SRS. Results: The 12-month local control was 72% after 20 Gy and 100% after 21-22.5 Gy (p=0.020). Freedom from new cerebral metastases (p=0.13) and survival (p=0.13) showed no association with SRS dose. On multivariate analyses, improved local control showed significant associations with SRS doses of 21-22.5 Gy (p=0.007) and normal lactate dehydrogenase levels (p=0.018). Improved survival was associated with normal LDH levels (p=0.006) and KPS 90-100 (p=0.046). Conclusion: SRS doses of 21-22.5 Gy resulted in better local control than 20 Gy. Freedom from new brain metastases and survival were not significantly different.

KW - Brain metastases

KW - Melanoma

KW - Radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=84908679374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908679374&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 5079

EP - 5082

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -